Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-1042 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.
Number of participants with abnormal change in physical examinations in areas like cardiovascular, respiratory, and neurological systems will be assessed.
12-lead resting ECG will be recorded.
Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed.
Cmax of ABBV-1042
Tmax of ABBV-1042
β of ABBV-1042
t1/2 of ABBV-1042
AUCt of ABBV-1042
AUCinf of ABBV-1042
| Arm | Type | Description |
|---|---|---|
| ABBV-1042 or Placebo-Group 1 | EXPERIMENTAL | Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
| ABBV-1042 or Placebo-Group 2 | EXPERIMENTAL | Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
| ABBV-1042 or Placebo-Group 3 | EXPERIMENTAL | Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
| ABBV-1042 or Placebo-Group 4 | EXPERIMENTAL | Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
| ABBV-1042 or Placebo-Group 5 | EXPERIMENTAL | Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
| ABBV-1042 or Placebo-Group 6 | EXPERIMENTAL | Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
| Name | Type | Description |
|---|---|---|
| ABBV-1042 | DRUG | Oral Solution |
| Placebo | DRUG | Oral Solution |
Inclusion Criteria: * BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters. * Body weight ˃ 45 kg at the time of screening and upon initial confinement. * A condition of general good hea...
ABBV-1042 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a trial assessing adverse events and how the drug moves through the body of healthy adult participants. It is not approved for any condition and remains in early-stage clinical testing.
ABBV-1042 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting a Phase 1 study of this oral small molecule in healthy volunteers in the United States.
ABBV-1042 is in Phase 1 clinical development. The ongoing trial is recruiting healthy adult participants in the United States to evaluate adverse events and how the oral drug moves through the body. It is an investigational drug and has not been approved by regulatory authorities.
ABBV-1042 is being studied in one active Phase 1 clinical trial, identified as NCT07222709. This randomized, double-blind, controlled study is recruiting 48 healthy adult participants in the United States to assess adverse events and how oral ABBV-1042 moves through the body.
Yes, ABBV-1042 is a small molecule drug. It is being developed as an oral formulation and is currently in a Phase 1 study involving healthy volunteers to evaluate its safety and pharmacokinetics. The trial is randomized, double-blind, and controlled.